X

Trial Profile

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 30 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Romiplostim (Primary)
Indications Thrombocytopenia
Focus Registrational; Therapeutic Use
Acronyms RECITE
Sponsors Amgen

Most Recent Events

24 Sep 2024 Planned End Date changed from 24 Jan 2025 to 6 Jan 2025.
06 Feb 2024 According to Amgen media release, Data readout is anticipated in H2 2024.
01 Feb 2024 Planned End Date changed from 23 Mar 2025 to 24 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com